Zephyr AI, Inc. has announced the successful closure of a $111 million Series A funding round. The round saw contributions from notable investors including Revolution Growth, Eli Lilly & Company, Jeff Skoll, and EPIQ Capital Group.

Zephyr AI is at the forefront of developing advanced Artificial Intelligence (AI) solutions aimed at democratizing precision medicine, particularly in the critical fields of oncology and cardiometabolic disease.

Grant Verstandig, the Co-Founder and Executive Chairman of Zephyr AI, emphasized the urgency of their mission in light of the United States’ high rate of avoidable cancer and cardiometabolic-related deaths. “We are committed to harnessing AI’s potential to generate new insights that will enhance patient stratification, response predictions, and the federation of real-world data,” Verstandig stated. The company’s deployment of one of the largest clinicogenomic datasets marks a significant stride towards achieving their goal of democratizing precision medicine.

Dr. Justin Stebbing, the Chairman of Zephyr AI’s Scientific and Medical Advisory Board, highlighted the company’s technological edge. “Zephyr AI’s technology not only adeptly navigates real-world patient data but also provides a biological context for its predictions, a critical factor in drug development,” Dr. Stebbing explained.

The influx of new capital will bolster Zephyr AI’s analytical capabilities and support the growth of its scientific and commercial teams. This expansion is set to fast-track the delivery of the company’s insights to the market, with Co-Founder, Interim CEO, and Chief Technology Officer Jeff Sherman stating, “Our enhanced data resources will expedite the evolution of our algorithms, transforming precision medicine and improving patient outcomes.”

Zephyr AI’s innovative research has earned it a spot at the upcoming American Association for Cancer Research (AACR) annual meeting in San Diego. The company will present two abstracts showcasing their latest advancements in clinicogenomics and molecular data augmentation.

As Zephyr AI continues to make waves in AI-enabled drug development, the healthcare community eagerly anticipates their contributions at AACR and beyond.

Tierra Biosciences secures $11.4M in Series A funding to revolutionize protein synthesis